Related Experiment Video
Updated: Jan 15, 2026
Double Direct Injection of Blood into the Cisterna Magna as a Model of Subarachnoid Hemorrhage
Published on: August 30, 2020
Prognostic factors in aneurysmal subarachnoid hemorrhage during the clazosentan era: a multicenter study using
Shinsuke Muraoka1, Takashi Izumi2, Kazuki Ishii2,3
1Department of Neurosurgery, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, Aichi, Japan. neuro-smuraoka@umin.ac.jp.
Insights
Controlling delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH) is key. Treatments like clazosentan, cilostazol, and statins significantly improve patient outcomes and prognosis.
Area of Science:
- Neurology
- Neurosurgery
- Critical Care Medicine
Background:
- Delayed cerebral ischemia (DCI) significantly impacts prognosis for aneurysmal subarachnoid hemorrhage (aSAH) patients.
- Identifying prognostic factors is crucial for optimizing patient outcomes in aSAH management.
Purpose of the Study:
- To identify key prognostic factors influencing outcomes in Japanese patients with aSAH.
- To evaluate the effectiveness of specific pharmacological interventions in preventing DCI and improving functional recovery.
Main Methods:
- A multicenter, retrospective observational cohort study involving 506 aSAH patients.
- Surgical aneurysm repair within 48 hours, followed by postoperative treatments including clazosentan and fasudil.
- Multivariate logistic regression and SHapley Additive exPlanations (SHAP) analysis to determine prognostic factors and their impact.
Main Results:
- 53.0% of patients achieved a favorable outcome (modified Rankin Scale 0-2).
- Clazosentan administration was associated with significantly higher odds of a favorable outcome (1.84-1.97 times).
- Lower WFNS/Fisher grades, younger age, and use of clazosentan, cilostazol, and statins were significant predictors of favorable outcomes.
Conclusions:
- While age and initial clinical status are uncontrollable, targeted DCI prevention is vital.
- Therapies including clazosentan, cilostazol, and statins show promise in improving functional outcomes for aSAH patients.
Background:
Controlling delayed cerebral ischemia (DCI) is crucial for improving the prognosis in patients with aneurysmal subarachnoid hemorrhage (aSAH). This study aimed to identify prognostic factors in patients with aSAH in Japan.
Methods:
A multicenter, retrospective, observational cohort study was conducted from April 2021 to March 2024. Patients underwent surgical repair of ruptured aneurysms within 48 h of onset, followed by postoperative treatment with multiple drugs, including clazosentan and fasudil, to prevent cerebral vasospasm. The primary outcome was the proportion of patients with a good outcome, defined as a modified Rankin Scale score of 0 to 2 at discharge. Multivariate logistic regression and stepwise model selection were applied to identify prognostic factors. SHapley Additive exPlanations (SHAP) analysis was used to visualize the relative importance of predictors and their impact on outcomes.
Results:
Among 506 patients (mean age 63.5 years, 66.6% female), 53.0% achieved a favorable outcome. In multivariate analysis, treatment with clazosentan was associated with 1.84 times higher odds of a favorable outcome (p = 0.021), increasing to 1.97 when clazosentan was administered without fluid retention complications (p = 0.010). SHAP analysis further highlighted the impact of each factor on prognosis, identifying a lower WFNS grade, lower Fisher grade, younger age, clazosentan, cilostazol, and statin use as significant predictors of favorable outcomes.
Conclusion:
Clinical status at aSAH onset and age are uncontrollable factors; therefore, improving prognosis requires targeted prevention of DCI and effective management of brain edema. The administration of therapies such as clazosentan, cilostazol, and statins may contribute to favorable outcomes.
Clinical Trial Number:
Not applicable.
More Related Videos
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
